Role of CD47 in Hematological Malignancies

Eladl, Entsar; Tremblay-Lemay, Rosemarie; Rastgoo, Nasrin; Musani, Rumina; Chen, Wen-Ming; Liu, Aijun; Chang, Hong

doi:10.1186/s13045-020-00930-1

Cited by 109 publications

(110 citation statements)

References 104 publications

(151 reference statements)

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…It is worth to mention that CD47 may mediate many different biologic activities besides its immunoregulatory functions. CD47 is not only a receptor for SIRP and the matricellular protein thrombospondin-1 (TSP-1), but also for ligands that are emerging [ 40 ]. Evidence has indicated that CD47 is a versatile factor in cell activity, such as in angiogenesis [ 41 , 42 ], cell migration, immune-cell filtration [ 43 ], as well as cell death [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

et al. 2021

View full text Add to dashboard Cite

Background Recent studies have suggested the important roles of CD47 and tumor-associated macrophages in the prognosis and immunotherapy of various human malignancies. However, the clinical significance of CD47 expression and CD163+ TAMs in pancreatic neuroendocrine tumor (PanNET) remains unclear. Methods In this study, 47 well-differentiated PanNET resection specimens were collected. CD47 expression and CD163+ macrophages were evaluated using immunohistochemistry and correlated with clinicopathologic properties. Results Positive CD47 staining was seen in all PanNETs as well as adjacent normal islets. Compared to normal islets, CD47 overexpressed in PanNETs (p = 0.0015). In the cohort, lymph node metastasis (LNM), lymphovascular invasion (LVI), and perineural invasion (PNI) were found in 36.2, 59.6, and 48.9% of the cases, respectively. Interestingly, PanNETs with LNM, LVI, or PNI had significantly lower H-score of CD47 than those without LNM (p = 0.035), LVI (p = 0.0005), or PNI (p = 0.0035). PanNETs in patients with disease progression (recurrence/death) also showed a significantly lower expression of CD47 than those without progression (p = 0.022). In contrast, CD163+ macrophage counts were significantly higher in cases with LNM, LVI, and PNI. Conclusions Our data suggest relative low CD47 expression and high CD163+ TAMs may act as indicators for poor prognosis of PanNETs.

show abstract

Section: Discussionmentioning

confidence: 99%

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, the correlation between U-CLL and CD38 expression was not found in another study [48]. Higher levels of CD47 are also related to U-CLL [49]. Compared to M-CLL, U-CLL is 4 times more likely to develop Richter syndrome (RS) [38].…”

Section: Ighv Mutation Statusmentioning

confidence: 95%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.

show abstract

“…Lately, enhanced CD47 expression was linked to CD123 expression and shown to be responsible for drug resistance in AML that could be overcome by treatment with the histone deacetylase inhibitor Romidepsin [ 126 ]. However, phase 1 trials using monoclonal anti-CD47 antibodies were terminated due to insufficient activity (CC-90002, NCT02641002) [ 127 ], life threatening side effects (Ti-061, 2016-004372-22; Hu5F9-g4, NCT02678338), or anemia (due to CD47 expression on red blood cells [ 128 ]). Results from other currently recruiting clinical trials are underway.…”

Section: Therapeutic Targeting Of Lscmentioning

confidence: 99%

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

Arnone

Konantz

Hanns

et al. 2020

Cancers

View full text Add to dashboard Cite

Patients suffering from acute myeloid leukemia (AML) show highly heterogeneous clinical outcomes. Next to variabilities in patient-specific parameters influencing treatment decisions and outcome, this is due to differences in AML biology. In fact, different genetic drivers may transform variable cells of origin and co-exist with additional genetic lesions (e.g., as observed in clonal hematopoiesis) in a variety of leukemic (sub)clones. Moreover, AML cells are hierarchically organized and contain subpopulations of more immature cells called leukemic stem cells (LSC), which on the cellular level constitute the driver of the disease and may evolve during therapy. This genetic and hierarchical complexity results in a pronounced phenotypic variability, which is observed among AML cells of different patients as well as among the leukemic blasts of individual patients, at diagnosis and during the course of the disease. Here, we review the current knowledge on the heterogeneous landscape of AML surface markers with particular focus on those identifying LSC, and discuss why identification and targeting of this important cellular subpopulation in AML remains challenging.

show abstract

Role of CD47 in Hematological Malignancies

Cited by 109 publications

References 104 publications

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

Contact Info

Product

Resources

About